Results 101 to 110 of about 3,975 (165)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

HIV/AIDS: Research and Palliative Care, 2018
Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract ...
Hill L, Smith SR, Karris MY
doaj  

Perinatal bictegravir exposure outcomes

BACKGROUND: Bictegravir (BIC) was recently transitioned from insufficient data in pregnancy to alternative antiretroviral therapy in pregnancy. Our study aimed to examine the perinatal and early infant outcomes following BIC exposure in pregnancy in ...
Kakkar, Fatima, Boucoiran, Isabelle, Lee, Terry, Bitnun, Ari, Singer, Joel, Money, Deborah M., Tse-Cheng, Alena, Balleny, Rosa, Brophy, Jason, McConnell, Athena, Comeau, Jeannette, Sauve, Laura, Wong, Jeffrey Man Hay   +12 more
core   +1 more source

Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir

Background: – Symptomatic cerebrospinal fluid (CSF) escape is an uncommon presentation in people with HIV with undetectable or low-level HIV RNA while on combination antiretroviral treatment (cART).
Guastamacchia, Giulia, Angilletta, Roberto, Mussa, Marco, Trunfio, Mattia, Bosio, Roberta, Romano, Francesca, Calitri, Carmelina, Bonora, Stefano, Calcagno, Andrea, Rizzello, Barbara, Lipani, Carola, Allice, Tiziano, Perinzano, Andrea, Di Perri, Giovanni   +13 more
core   +1 more source

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1.
Sklar, Peter, Santana, Jorge, Aizen, Keith, Mounzer, Karam, Hedgcock, Malcolm, Montezuma-Rusca, Jairo M., Zhang, Xu, Bloch, Mark, Segal-Maurer, Sorana, Slim, Jihad, Ramgopal, Moti   +10 more
core   +1 more source

Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain. [PDF]

EClinicalMedicine
Chivite I, Moraga E, Sempere A, Vicens-Artés S, Callau P, Rovira C, Hurtado C, De Nicoló A, Sánchez-Molina A, Torres B, Blanch J, Alcamí J, Blanco JL, D'Avolio A, Sánchez-Palomino S, De Lazzari E, Martínez E.   +16 more
europepmc   +1 more source

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations

Resistance-associated mutations (RAMs) limit treatment options for HIV. We evaluated virologic outcomes in people with HIV harboring RAMs who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world cohort during 4 years of ...
Edgardo Bottaro, Lidia I. Cassetti, Cinthia S. Lamaizón, Martin Brizuela, Macarena Roel, Diego Cecchini, Brenda Bacelar, Gastón Copertari   +7 more
core   +1 more source

Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV on Any Antiretroviral Therapy Regimen: The Retrospective ESSENTIAL Study. [PDF]

Infect Dis Ther
Cossu MV, Moschese D, Matone M, Oreni L, Carrozzo G, Poloni A, Pozza G, Albini L, Forcina G, Gervasoni C, Riva A, Giacomelli A, Gori A.   +12 more
europepmc   +1 more source

Voriconazole therapeutic drug monitoring and safety in HIV-infected patients with invasive fungal disease. [PDF]

Front Pharmacol
Hu L, Su Y, Hou J, Li Y, He C.
europepmc   +1 more source

Twice-daily bictegravir during rifampicin-based tuberculosis therapy: A pragmatic alternative. [PDF]

HIV Med
Sánchez-Cano JG, Muñoz-Echeverría L, Casco-García M, Moreno-Núñez L.   +3 more
europepmc   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source